Literature DB >> 11579684

Immunohistochemical analysis of p27 (Kip1) in human pituitary glands and in various types of pituitary adenomas.

K Komatsubara1, S Tahara, K Umeoka, N Sanno, A Teramoto, R Y Osamura.   

Abstract

p27 (Kip1) plays regulatory roles in the cell cycle by inhibiting the activity of cyclin dependent kinases (CDKs). This immunohistochemical study is aimed at elucidating the expression of p27 in human pituitary and in various types of pituitary adenomas in order to clarify its role in the regulation of proliferation. Sixteen normal pituitary glands and 179 human pituitary adenomas were used for immunohistochemical studies. The tissues were fixed in 10% formalin and embedded in paraffin. Indirect peroxidase method was performed after heat-induced antigen retrieval using a monoclonal antibody against p27 protein. p27 protein was expressed in the nuclei of all 16 normal human pituitary glands. p27 protein was also expressed in 128 of 179 cases of pituitary adenomas (71.5%). A marked decrease of p27 expression was noted in ACTH-secreting adenomas, 8/20 (40.0%), compared with other types of pituitary adenomas--GH-secreting adenomas, 35/46 (76.1%); PRL-secreting adenomas, 22/33 (66.7%); TSH-secreting adenomas, 8/11 (72.7%); and nonfunctioning adenomas, 55/69 (79.7%). These results suggest that p27 may play some role in the regulation of proliferation in all types of pituitary adenomas. The lower levels of p27 in ACTH-secreting adenoma is of particular interest with respect to the intermediate lobe-derived pituitary tumor developed in p27 knockout mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579684     DOI: 10.1385/ep:12:2:181

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  32 in total

1.  Effects of cyclin D1 overexpression on G1 progression-related events.

Authors:  M Imoto; Y Doki; W Jiang; E K Han; I B Weinstein
Journal:  Exp Cell Res       Date:  1997-10-10       Impact factor: 3.905

2.  Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index.

Authors:  M Sánchez-Beato; A I Sáez; J C Martínez-Montero; M Sol Mateo; L Sánchez-Verde; R Villuendas; G Troncone; M A Piris
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

3.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

4.  Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines.

Authors:  K Kitahara; W Yasui; H Yokozaki; S Semba; T Hamamoto; T Hisatsugu; E Tahara
Journal:  J Exp Ther Oncol       Date:  1996-01

5.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

6.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

7.  Cyclin-dependent kinase inhibitor p27kip1 is expressed at high levels in cells that express a myelinating phenotype.

Authors:  A J Friessen; W K Miskimins; R Miskimins
Journal:  J Neurosci Res       Date:  1997-11-01       Impact factor: 4.164

8.  Hormone-induced proliferation and differentiation of granulosa cells: a coordinated balance of the cell cycle regulators cyclin D2 and p27Kip1.

Authors:  R L Robker; J S Richards
Journal:  Mol Endocrinol       Date:  1998-07

9.  TGFB, TGFB Receptors, Ki-67, and p27(Kip)l Expression in Papillary Thyroid Carcinomas.

Authors:  Ricardo V. Lloyd; Jorge A. Ferreiro; Long Jin; Tom J. Sebo
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences.

Authors:  B O Williams; E M Schmitt; L Remington; R T Bronson; D M Albert; R A Weinberg; T Jacks
Journal:  EMBO J       Date:  1994-09-15       Impact factor: 11.598

View more
  7 in total

1.  Aggressive vestibular schwannomas showing postoperative rapid growth - their association with decreased p27 expression.

Authors:  Ho Jun Seol; Hee-Won Jung; Sung-Hye Park; Sung-Kyun Hwang; Dong Gyu Kim; Sun Ha Paek; Young-Seob Chung; Chang Sub Lee
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 2.  Recent progress in studies of pituitary tumor pathogenesis.

Authors:  Takeo Minematsu; Shunsuke Miyai; Hanako Kajiya; Masanori Suzuki; Naoko Sanno; Susumu Takekoshi; Akira Teramoto; Robert Y Osamura
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

3.  E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors.

Authors:  Cuiqi Zhou; Kolja Wawrowsky; Serguei Bannykh; Shiri Gutman; Shlomo Melmed
Journal:  Mol Endocrinol       Date:  2009-10-16

Review 4.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

Review 5.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

6.  Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly.

Authors:  Juan F Martín-Rodríguez; Jose L Muñoz-Bravo; Alejandro Ibañez-Costa; Laura Fernandez-Maza; Marcin Balcerzyk; Rocío Leal-Campanario; Raúl M Luque; Justo P Castaño; Eva Venegas-Moreno; Alfonso Soto-Moreno; Alfonso Leal-Cerro; David A Cano
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

Review 7.  Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease.

Authors:  Takako Araki; Ning-Ai Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-10       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.